Study shows Lucid's EsoGuard test detects esophageal precancer in at-risk patients without symptoms. Read more here.

Lucid Diagnostics (LUCD) announced positive data from a National Cancer Institute-sponsored study demonstrating that its EsoGuard Esophageal ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced ...

These results support EsoGuard esophageal precancer testing in an expanded target population, consistent with existing American Gastroenterological Association (AGA) guidelines and has the ...

Lucid Diagnostics (NASDAQ:LUCD) reported positive data from a study showing that its EsoGuard esophageal DNA test can detect esophageal precancer in at-risk patients who don’t show typical ...

Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing For more information about Lucid, please visit www.luciddx.com and for more information about ...

Lucid Diagnostics shared new data from a National Cancer Institute (NCI)-sponsored study that supports the broader utility of its EsoGuard(R) Esophageal DNA Test. The study, condu ...